美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Eleven Biotherapeutics Inc.

3.29

+0.0000

成交量：- -

成交额：- -

市值：1.59亿

市盈率：-3.37

高：3.29

开：3.29

低：3.29

收：3.29

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Eleven Biotherapeutics Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.elevenbio.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Eleven Biotherapeutics, Inc.是临床阶段生物制药公司，拥有一个专有的蛋白质工程平台，称为 AMP-Rx，它用于发现和发展蛋白质疗法来治疗眼疾。其治疗方法基于在有疾病的眼睛中的细胞因子，以及它对细胞因子的结构认知和理性设计操控蛋白质调节细胞因子影响的能力。细胞因子是细胞信号分子，在可以产生重要的炎症部分上发现。该公司认为细胞因子在许多眼部疾病的基本病理机制中发挥重要作用，蛋白质疗法是调节眼睛的疾病中细胞因子的影响的有效手段。该公司已利用其 AMP Rx 平台理性设计、操控和生成创新性蛋白治疗候选药物渠道把细胞因子作为靶子，并认为这是控制眼疾的关键。该公司现正进行针对前面的眼睛疾病，包括干眼症疾病和过敏性结膜炎等疾病和后面的眼睛，糖尿病黄斑水肿或二甲醚和葡萄膜炎等疾病的研究和发展方案。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/EBIO/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EBIO\",,,,,undefined,":{"symbol":"EBIO","market":"US","secType":"STK","nameCN":"Eleven Biotherapeutics Inc.","latestPrice":3.29,"timestamp":1526500800000,"preClose":3.29,"halted":4,"volume":0,"delay":0,"floatShares":6754972,"shares":48390072,"eps":-0.976817,"marketStatus":"退市","change":0,"latestTime":"04-29 13:21:36 EDT","open":3.29,"high":3.29,"low":3.29,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.976817,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"symbolChange":{"newSymbol":"SESN","executeDate":"2018-05-17"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.29,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EBIO\",,,,,undefined,":{"symbol":"EBIO","floatShares":6754972,"roa":"--","roe":"--","lyrEps":0,"shares":48390072,"dividePrice":0,"high":3.29,"amplitude":0,"preClose":3.29,"low":3.29,"week52Low":0.6201,"pbRate":"6.67","week52High":3.5,"institutionHeld":0,"latestPrice":3.29,"eps":-0.976817,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.976817,"open":3.29},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.elevenbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.0503},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0601}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Eleven Biotherapeutics, Inc.是临床阶段生物制药公司，拥有一个专有的蛋白质工程平台，称为 AMP-Rx，它用于发现和发展蛋白质疗法来治疗眼疾。其治疗方法基于在有疾病的眼睛中的细胞因子，以及它对细胞因子的结构认知和理性设计操控蛋白质调节细胞因子影响的能力。细胞因子是细胞信号分子，在可以产生重要的炎症部分上发现。该公司认为细胞因子在许多眼部疾病的基本病理机制中发挥重要作用，蛋白质疗法是调节眼睛的疾病中细胞因子的影响的有效手段。该公司已利用其 AMP Rx 平台理性设计、操控和生成创新性蛋白治疗候选药物渠道把细胞因子作为靶子，并认为这是控制眼疾的关键。该公司现正进行针对前面的眼睛疾病，包括干眼症疾病和过敏性结膜炎等疾病和后面的眼睛，糖尿病黄斑水肿或二甲醚和葡萄膜炎等疾病的研究和发展方案。","exchange":"NASDAQ","name":"Eleven Biotherapeutics Inc.","nameEN":"Eleven Biotherapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"EBIO\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EBIO\",params:#limit:5,,,undefined,":[{"date":"2018-05-17","symbol":"EBIO","newSymbol":"SESN","type":"symbolChange","dateTimestamp":1526529600000},{"market":"US","date":"2018-05-15","symbol":"EBIO","fiscalQuarterEnding":"2018/03","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.11},{"market":"US","date":"2018-04-04","symbol":"EBIO","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1522814400000,"reportTimeType":"","actualEps":-0.22},{"market":"US","date":"2017-11-20","symbol":"EBIO","name":"Eleven Biotherapeutics Inc.","time":"","type":"earning","dateTimestamp":1511154000000,"reportTimeType":"","actualEps":-0.37},{"market":"US","date":"2017-11-14","symbol":"EBIO","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1510635600000,"reportTimeType":"pre","actualEps":0.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EBIO\",market:\"US\",delay:false,,,undefined,":{}}}